Skip to content

Grant Income at other companies

Starfighters Space, Inc.
 logo
Starfighters Space, Inc. FJET
$24K-40.0%
Kopin logo
KopinKOPN
$3.44M+1,504%
Ondas, Inc.
 logo
Ondas, Inc. ONDS
$317+95.7%
Espey Manufacturing & Electronics Corp. logo
Espey Manufacturing & Electronics Corp.ESP
$1.01M+24.5%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$4.34M+4.5%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$1.36M+33.7%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept hura:GrantIncome.

The official record: TuHURA Biosciences, Inc.’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s grant income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s grant income?
TuHURA Biosciences, Inc. (HURA) reported grant income of $0 in Q4 2025.
How has TuHURA Biosciences, Inc.'s grant income changed year-over-year?
TuHURA Biosciences, Inc.'s grant income decreased by 100.0% year-over-year, from $14.41K to $0.
What is the long-term trend for TuHURA Biosciences, Inc.'s grant income?
Over 2 years (2023 to 2025), TuHURA Biosciences, Inc.'s grant income has grown at a 309.9% compound annual growth rate (CAGR), from $42.47K to $713.51K.
What does grant income mean?
Represents non-dilutive funding received from government agencies, non-profits, or research institutions to support specific development programs. This income is critical for biotechnology companies to offset high research and development costs without issuing additional equity. It serves as a measure of external validation for the company's scientific research and development pipeline.